Specifically, the promising approach of targeting dysregulated miRNAs such as miR-26a and miR-30b has been found to enhance the efficiency of trastuzumab therapy for HER2-positive (HER+) breast cancer by improving sensitivity (Liu J. et al., 2018). Here, ERBB2 is linked to breast cancer.